DAVID ATKINS: Open Payments
NPI 1003142852 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$686 in 29 payments from 15 companies in 2025. Trend: 2023 $563 · 2024 $126 · 2025 $686
Food & beverage: $686
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $201 |
| Lilly USA, LLC | 8 | $158 |
| Gilead Sciences, Inc. | 4 | $80 |
| Novo Nordisk Inc | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Verona Pharma, Inc. | 1 | $23 |
| Merck Sharp & Dohme LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| SANOFI-AVENTIS U.S. LLC | 1 | $17 |
Products named: MOUNJARO, FARXIGA, AIRSUPRA, Wegovy, Jornay PM, Ohtuvayre, LAGEVRIO, GIVLAARI.
Industry payments across KY — which companies pay providers there.
